about
Galactomannan detection for invasive aspergillosis in immunocompromised patientsHigh-frequency triazole resistance found In nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal diseaseHow to manage aspergillosis in non-neutropenic intensive care unit patientsGalactomannan testing of bronchoalveolar lavage fluid is useful for diagnosis of invasive pulmonary aspergillosis in hematology patients.Development of a novel inhalational model of invasive pulmonary aspergillosis in rats and comparative evaluation of three biomarkers for its diagnosis.Innate Lung Defense during Invasive Aspergillosis: New Mechanisms.Detection of galactomannan in bronchoalveolar lavage of the intensive care unit patients at risk for invasive aspergillosisFungal diagnostics in pneumoniaSystematic review and meta-analysis of detecting galactomannan in bronchoalveolar lavage fluid for diagnosing invasive aspergillosisPractice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes.Evaluation of MycAssay™ Aspergillus for diagnosis of invasive pulmonary aspergillosis in patients without hematological cancer.Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomesBeta-D-glucan detection as a diagnostic test for invasive aspergillosis in immunocompromised critically ill patients with symptoms of respiratory infection: an autopsy-based studyMulticenter evaluation of a lateral-flow device test for diagnosing invasive pulmonary aspergillosis in ICU patientsDiagnosis of invasive aspergillosis by a commercial real-time PCR assay for Aspergillus DNA in bronchoalveolar lavage fluid samples from high-risk patients compared to a galactomannan enzyme immunoassay.Invasive pulmonary aspergillosis accompanied by soft tissue lesions during treatment of a patient with hyperthyroidism: a case report.Detection and measurement of fungal burden in a guinea pig model of invasive pulmonary aspergillosis by novel quantitative nested real-time PCR compared with galactomannan and (1,3)-β-D-glucan detectionDetection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: analytical and clinical validity.Pulmonary aspergillosis: clinical presentation, diagnostic tests, management and complications.Fatal Case of Probable Invasive Aspergillosis after Five Years of Heart Transplant: A Case Report and Review of the LiteratureFungal infections: their diagnosis and treatment in transplant recipients.Putative invasive pulmonary aspergillosis in critically ill patients with chronic obstructive pulmonary disease: a matched cohort study.Clinical risk factors and bronchoscopic features of invasive aspergillosis in intensive care unit patientsInvasive fungal infections in acute leukemia.Role of galactomannan determinations in bronchoalveolar lavage fluid samples from critically ill patients with chronic obstructive pulmonary disease for the diagnosis of invasive pulmonary aspergillosis: a prospective studyDoes galactomannan testing increase diagnostic accuracy for IPA in the ICU? A prospective observational study.Invasive Aspergillus infections in hospitalized patients with chronic lung diseaseAspergillus-positive lower respiratory tract samples in patients with the acute respiratory distress syndrome: a 10-year retrospective study.Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts?Laboratory diagnosis of invasive aspergillosis: from diagnosis to prediction of outcomeManagement of invasive aspergillosis in patients with COPD: rational use of voriconazole.Invasive fungal infections in patients with cancer in the Intensive Care Unit.Invasive mold infections: recent advances in management approaches.SIMIFF study: Italian fungal registry of mold infections in hematological and non-hematological patients.Invasive fungal tracheobronchitis in mechanically ventilated critically ill patients: underlying conditions, diagnosis, and outcomes.Galactomannan antigen assay from bronchoalveolar lavage fluid in diagnosis of invasive pulmonary aspergillosis in intensive care units patientsInvasive fungal infections in the ICU.Challenges in microbiological diagnosis of invasive Aspergillus infections.Current aspects of invasive candidiasis and aspergillosis in adult intensive care patients.
P2860
Q24186895-F64AF061-F713-4380-8C74-0E5969799090Q24628838-9D4B4E8E-B859-4B76-B38A-628C102E3FBDQ26999448-6AB198B4-708C-4F96-B417-3709C4A0B740Q30978790-4F573E26-9A78-4F04-89D4-7DF07993C97FQ33793571-0C4CEFF2-5A18-40D0-9B10-C3B0D216A035Q33810700-99C55BD9-3CAD-474E-B4A6-700B7C832B65Q33851382-9BBF5CCA-7B14-4BCD-9F3E-3E98C78CDC19Q34153565-17C833C2-4E36-475E-A650-DF42C7454B4EQ34385038-CD8221AE-7EA5-43CB-A53C-A20D08A8A66CQ34532546-A81C9345-3CF5-47B7-8200-4E82DC325956Q34559978-A4CE5D6D-552B-4344-A92A-1592F203C596Q34688953-796A5183-97A7-4937-9A2B-544DA15B3482Q35131913-72370BF1-899A-496D-8429-5524BE7164FDQ35530416-7FFB4AB2-BC9C-4E84-A772-C180C3A88CFBQ35575320-A6194C0B-2AF2-405C-88B6-6E2EF26CDA24Q35599066-27CF6F5A-16BB-4954-B0D0-2FB4E6B0E996Q35756322-0496D586-878D-4E8E-B61C-A9829EEF4F60Q35806998-FAFBA995-B6E2-49D6-8EFB-40E354DBCB89Q35867884-4BA2F0FA-6A3D-4643-8091-4671F2406CCEQ35889014-B05101B9-3676-4ED9-93C3-B70C0FAD6A4BQ36032018-0B5F16AA-3316-4C27-9955-D00C0EA62DD5Q36206568-F684265D-B112-4C3A-B132-319840D2398AQ36344062-F228A948-D458-42D4-91A0-5AD354332573Q36478542-FEC3E575-11E2-417A-9122-F6C399138CADQ36612597-CFC51ECE-85C7-4C38-8826-3AF6C22B912FQ36633947-15B99B3E-C058-4BAE-9858-982B9D11288FQ36886708-16061C54-1F23-4251-A094-AF574F42FCE5Q36906082-DF437EE8-4A01-42BB-96CD-745A28E76C3AQ36999971-710F7CFF-32B6-4A9D-8894-1C29F60E3F9BQ37098160-8DC0F411-F3CA-4961-96C5-E2A4B3D4917EQ37287794-8E901DD0-AF0D-4899-B7D1-4708E9D02C3AQ37294689-FEFE4B58-6EAA-4B5C-97D3-5232EA780203Q37373771-646194EA-6E29-4F23-810A-8359E3517484Q37428946-457DB5CA-A1C7-4275-8692-4E526BE17672Q37530914-BE73A465-A0AC-4D53-996B-7BCCA3D87375Q37583916-C4F25492-A7E8-4E53-A16D-E5FB792600A7Q37632011-93F4568F-0B16-4086-9608-0C0939B9444FQ37643057-1E3D2871-1150-4768-8ABC-C547A4748E82Q37659157-4653B932-798A-4695-8DE0-FEDCB5C30095Q37759256-9F7591ED-B746-475D-9E0A-6FF7DA026354
P2860
description
im Januar 2008 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в січні 2008
@uk
name
Galactomannan in Bronchoalveolar Lavage Fluid
@en
Galactomannan in Bronchoalveolar Lavage Fluid
@nl
type
label
Galactomannan in Bronchoalveolar Lavage Fluid
@en
Galactomannan in Bronchoalveolar Lavage Fluid
@nl
prefLabel
Galactomannan in Bronchoalveolar Lavage Fluid
@en
Galactomannan in Bronchoalveolar Lavage Fluid
@nl
P2093
P2860
P1476
Galactomannan in Bronchoalveolar Lavage Fluid
@en
P2093
Alexander Wilmer
Eric Van Wijngaerden
Eric Verbeken
Isabel Spriet
Johan Maertens
Katrien Lagrou
Wouter Meersseman
P2860
P356
10.1164/RCCM.200704-606OC
P407
P577
2008-01-01T00:00:00Z